Docoh
Loading...

GWPRF GW Pharmaceuticals

GRANT
Utility
Parenteral formulations
25 Jan 22
The present invention relates to parenteral cannabinoid formulations, and more particularly to cannabinoid containing intravenous (IV) formulations.
Stephen Wright, Jitinder Wilkhu
Filed: 29 Jun 17
GRANT
Utility
Cannabidiol preparations and its uses
28 Dec 21
Cannabidiol (CBD) is a cannabinoid designated chemically as 2-[(1R,6R)-3-Methyl-6-(1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzenediol.
Geoffrey Guy, Volker Knappertz, Benjamin Whalley, Marie Woolley-Roberts, James Brodie, Katarzyna Lach-Falcone, Alan Sutton, Royston Gray, Rohini Rajyalaxmi Rana
Filed: 3 Sep 20
GRANT
Utility
pH dependent release coated microparticle cannabinoid formulations
2 Nov 21
The present disclosure provides a microparticulate comprising one or more cannabinoids and a pH dependent release polymer.
Jitinder Wilkhu, Alan Silcock
Filed: 12 Oct 20
GRANT
Utility
Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
2 Nov 21
The present disclosure provides methods of treating tuberous sclerosis complex comprising administering cannabidiol and everolimus.
Geoffrey Guy, Volker Knappertz, Eduardo Dunayevich, David Critchley
Filed: 1 Mar 21
GRANT
Utility
Use of cannabinoids in the treatment of epilepsy
26 Oct 21
The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE).
Geoffrey Guy, Stephen Wright, Orrin Devinsky
Filed: 11 Dec 20
GRANT
Utility
Use of cannabinoids in the treatment of epilepsy
26 Oct 21
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures.
Geoffrey Guy, Stephen Wright, Orrin Devinsky
Filed: 27 Apr 21
GRANT
Utility
7-OH-cannabidiol (7-OH-CBD) and/or 7-OH-cannabidivarin (7-OH-CBDV) for use in the treatment of epilepsy
19 Oct 21
The present invention relates to the use of 7-hydroxy-cannabidol (7-OH-CBD) and/or 7-hydroxy-cannabidivarin (7-OH-CBDV) in the treatment of epilepsy.
Colin Stott, Nick Jones, Benjamin Whalley, Gary Stephens, Claire Williams
Filed: 3 Oct 19
GRANT
Utility
Use of cannabinoids in the treatment of epilepsy
19 Oct 21
The present invention relates to the use of a therapeutically effective amount of cannabidiolic acid (CBDA) in the treatment of epilepsy.
Colin Stott, Nicholas Jones, Robin Williams, Benjamin Whalley
Filed: 29 Jul 16
GRANT
Utility
Use of cannabinoids in the treatment of epilepsy
24 Aug 21
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures.
Geoffrey Guy, Stephen Wright, Orrin Devinsky
Filed: 11 Mar 21
GRANT
Utility
Use of cannabidiol in the treatment of epilepsy
20 Jul 21
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC).
Geoffrey Guy, Stephen Wright, Elizabeth Thiele
Filed: 12 Jan 21
GRANT
Utility
Use of cannabinoids in the treatment of multiple myeloma
20 Jul 21
The present invention relates to the use of a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) in the treatment of multiple myeloma.
Colin Stott, Massimo Nabissi
Filed: 31 Jul 17
GRANT
Utility
Combination of cannabinoids in the treatment of leukaemia
11 May 21
The present invention relates to the use of a combination of two different cannabinoids in the treatment of leukaemia.
Stephen Wright, Wai Liu, Katherine Scott, Angus Dalgleish
Filed: 16 Feb 18
GRANT
Utility
Use of cannabinoids in the treatment of epilepsy
6 Apr 21
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures.
Geoffrey Guy, Stephen Wright, Orrin Devinsky
Filed: 25 Jun 20
GRANT
Utility
Use of cannabidiol in the treatment of epilepsy
16 Feb 21
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC).
Geoffrey Guy, Stephen Wright, Elizabeth Thiele
Filed: 13 Oct 15
GRANT
Utility
Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders
26 Jan 21
The present invention relates to the use of cannabidiolic acid (CBDA) in the treatment of autism spectrum disorder (ASD) and ASD-associated disorders, such as Fragile X syndrome (FXS); Rett syndrome (RS); or Angelman syndrome (AS).
Geoffrey Guy, Stephen Wright, James Brodie, Marie Woolley-Roberts, Rafael Maldonado, Daniela Parolaro, Livio Luongo
Filed: 11 Apr 17
GRANT
Utility
Use of cannabinoids in the treatment of epilepsy
30 Nov 20
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures.
Geoffrey Guy, Stephen Wright, Orrin Devinsky
Filed: 20 Nov 18
GRANT
Utility
Pharmaceutical formulation
19 Oct 20
The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray.
Brian Anthony Whittle
Filed: 2 Dec 19
GRANT
Utility
Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
12 Oct 20
This invention relates to the use of the phytocannabinoid cannabidivarin (CBDV) and combinations of the phytocannabinoid CBDV with tetrahydrocannabivarin (THCV) and cannabidiol (CBD) in the treatment of epilepsy.
Ben Whalley, Claire Williams, Gary Stephens, Takashi Futamura
Filed: 13 Apr 15
GRANT
Utility
Use of cannabidiol in the treatment of epilepsy
7 Sep 20
The present disclosure relates to the use of cannabidiol (CBD) for the treatment of seizures associated with Aicardi Syndrome.
Geoffrey Guy, Stephen Wright, Orrin Devinsky
Filed: 13 Oct 15
GRANT
Utility
Use of tetrahydrocannabinol and/or cannabidiol for increasing radiosensitivity in the treatment of a brain tumour
31 Aug 20
The present invention relates to the use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer.
Wai Liu, Katherine Scott, Angus Dalgleish, Marnie Duncan, Colin Stott
Filed: 1 May 18
Patents are sorted by USPTO publication date, most recent first